Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide ...

Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline ...

the Company attended several key industry conferences to promote awareness among clinicians of the DurAVR ® THV system as a potential new treatment paradigm for aortic stenosis. These activities ...

Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that Linda Ramirez will join the Company as Chief Legal Officer. Linda has nearly 30 ...

Social media has reshaped stakeholder power, making strategic engagement essential. Learn how transparency, real-time ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fractyl Health, Inc. Common Stock misses on earnings expectations. Reported EPS is $-0.52 EPS, expectations were $-0.44. Operator: Good afternoon, and ...

To go into more detail, CIMB Securities said some of the 560 million units will be offered via an initial public offering or IPO ... of BTSC and Paradigm Mall Johor Baru,” the research house ...

Dr Ignatius Luke Chan, PhD, ACLP, investigates the current technological revolution and changes in the research paradigm of ...

Workforce readiness and retention strategies are critical to sustain business stability during and after the transition.

and the VIX Volatility Index is above 25,” said Matthew Kennedy, senior strategist at Renaissance Capital, a provider of pre-IPO research and IPO-focused exchange-traded funds.

CoreWeave, a hyperscaler startup backed by Nvidia, is targeting a valuation of up to $26 billion with its IPO.